GlassScriptPhysician profile
Jean Claude Hage
NPI 1982646832
$2,829.09
in general payments reported to CMS, 2019-2025
22 companies · $616 in 2025
The $616 reported for 2025 was more than what 77% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $533 · 2020: $56.95 · 2021: $294 · 2022: $506 · 2023: $368 · 2024: $456 · 2025: $616.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,440.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,439.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $906.01 | 2021-2025 | Austedo Xr, Austedo Xr, Austedo |
| Urovant Sciences INC | $347.47 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $339.82 | 2019-2023 | Xarelto |
| Merck Sharp & Dohme LLC | $185.06 | 2020-2024 | Verquvo |
| Alpha Cognition USA, INC. | $166.94 | 2025 | Zunveyl |
| Cardinal Health 200 LLC | $114.05 | 2019 | |
| Sunovion Pharmaceuticals INC. | $104.56 | 2019 | |
| Ucb, INC. | $98.57 | 2024-2025 | Fintepla, Nayzilam |
| Sumitomo Pharma America, INC. | $80.42 | 2023-2025 | Gemtesa |
| Astrazeneca Pharmaceuticals LP | $66.14 | 2020-2024 | Farxiga |
| Sanofi-Aventis U.S. LLC | $63.29 | 2019-2025 | |
| Otsuka America Pharmaceutical, INC. | $60.17 | 2023-2025 | Rexulti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $57.72 | 2021-2022 | |
| Lilly USA, LLC | $50.80 | 2021-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $38.35 | 2025 | Caplyta |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $32.23 | 2023 | |
| Glaxosmithkline, LLC. | $31.80 | 2023-2024 | Shingrix, Trelegy Ellipta, Arexvy |
| Melinta Therapeutics, LLC | $22.95 | 2019 | |
| Pfizer INC. | $18.68 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $17.10 | 2021 | |
| Scilex Pharmaceuticals INC. | $15.93 | 2023 | Ztlido |
| Allergan, INC. | $11.03 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jean Hage listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.